Evidence map›Paper›PMID 32291451›Full record

ArticleNeuro-oncology2020

1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine treatment after brain irradiation preserves cognitive function in mice.

Kruttika Bhat, Paul Medina, Ling He, Le Zhang, Mohammad Saki, Angeliki Ioannidis, Nhan T Nguyen, Sirajbir S Sodhi, David Sung, Clara E Magyar and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kruttika BhatDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Paul MedinaDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Ling HeDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Le ZhangDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Mohammad SakiDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Angeliki IoannidisDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Nhan T NguyenDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Sirajbir S SodhiDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
David SungDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Clara E MagyarTranslational Pathology Core Laboratory, Image Analysis/Virtual Microscopy, Department of Pathology and Laboratory Medicine, Los Angeles, California.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Harley I KornblumNPI-Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
University of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer Center

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Glioblastoma, Glioblastoma Stem Cells and RadiotherapyR01CA200234 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJONK, FRANK · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA200234NIAID NIH HHS U19 AI067769
6 · The paper itself

Abstract

backgroundNormal tissue toxicity is an inevitable consequence of primary or secondary brain tumor radiotherapy. Cranial irradiation commonly leads to neurocognitive deficits that manifest months or years after treatment. Mechanistically, radiation-induced loss of neural stem/progenitor cells, neuroinflammation, and demyelination are contributing factors that lead to progressive cognitive decline.

methodsThe effects of 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine (NSPP) on irradiated murine neurospheres, microglia cells, and patient-derived gliomaspheres were assessed by sphere-formation assays, flow cytometry, and interleukin (IL)-6 enzyme-linked immunosorbent assay. Activation of the hedgehog pathway was studied by quantitative reverse transcription PCR. The in vivo effects of NSPP were analyzed using flow cytometry, sphere-formation assays, immunohistochemistry, behavioral testing, and an intracranial mouse model of glioblastoma.

resultsWe report that NSPP mitigates radiation-induced normal tissue toxicity in the brains of mice. NSPP treatment significantly increased the number of neural stem/progenitor cells after brain irradiation in female animals, and inhibited radiation-induced microglia activation and expression of the pro-inflammatory cytokine IL-6. Behavioral testing revealed that treatment with NSPP after radiotherapy was able to successfully mitigate radiation-induced decline in memory function of the brain. In mouse models of glioblastoma, NSPP showed no toxicity and did not interfere with the growth-delaying effects of radiation.

conclusionsWe conclude that NSPP has the potential to mitigate cognitive decline in patients undergoing partial or whole brain irradiation without promoting tumor growth and that the use of this compound as a radiation mitigator of radiation late effects on the central nervous system warrants further investigation.

Indexed as

CognitionHedgehog ProteinsAnimalsBrainCranial IrradiationFemaleMiceMice, Inbred C57BLPiperazinesHedgehog ProteinsphenylpiperazinePiperazinescognitive functionneural stem cellsradiationradiation mitigation

Identifiers

PMID32291451
PMCPMC7566405
OpenAlexW3015339014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.